Results 201 to 210 of about 182,278 (349)

The clinical heterogeneity of RUNX1 associated familial platelet disorder with predisposition to myeloid malignancy - A case series and review of the literature. [PDF]

Res Pract Thromb Haemost, 2020
Tang C, Rabbolini DJ, Morel-Kopp MC, Connor DE, Crispin P, Ward CM, Stevenson WS.   +6 more
europepmc   +1 more source

Platelet function analyzer (PFA)‐100®closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal [PDF]

, 2006
Catherine P.M. Hayward, Paul Harrison, Marco Cattaneo, Thomas L. Ortel, A. Koneti Rao   +4 more
openalex   +1 more source

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

Advanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei, Wuqiang Wen, Wenjun Zhang, Shujing Zhang, Ting Sun, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao, Aibin Liang, Baishan Jiang, Jing Yang   +32 more
wiley   +1 more source

Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in <i>RUNX1</i>-familial platelet disorder. [PDF]

Sci Transl Med
Mohammadhosseini M, Enright T, Duvall A, Chitsazan A, Lin HY, Ors A, Davis BA, Nikolova O, Bresciani E, Diemer J, Craft K, Menezes AC, Merguerian M, Chong S, Calvo KR, Deuitch NT, Glushakow-Smith S, Gritsman K, Godley LA, Horwitz MS, Keel S, Castilla LH, Demir E, Mohammed H, Liu P, Agarwal A.   +25 more
europepmc   +1 more source

Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts. [PDF]

Int J Lab Hematol, 2020
Hayward CPM, Tasneem S, Rivard GE.
europepmc   +1 more source

[Allogeneic hematopoietic stem cell transplantation for Familial platelet disorder with a propensity for acute myeloid malignancies with Runx1 germline mutations: a case report and literature review]. [PDF]

Zhonghua Xue Ye Xue Za Zhi, 2022
Wang LL, Guan J, Cheng P, Zhang T, Cheng H, Zou L.   +5 more
europepmc   +1 more source

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen, Rui Li, Yong She, Xuefei Liu, Yuanyang Huang, Yongling Ji, Keying Chen, Zhengbo Song, Runzhe Chen, Xuan Li, Qi Zhao, Qixun Chen, Ming Chen   +12 more
wiley   +1 more source

Bernard-Soulier Syndrome: An Inherited Platelet Disorder [PDF]

, 2002
Sivajee Sengupta
openalex   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source